NCT02011503已完成不适用
A Randomized Controlled Clinical Trial Evaluating The Application Of Dehydrated Human Amnion/ Chorion Membrane (dHACM) Plus Standard Of Care Vs. Standard Of Care Alone In The Treatment Of Venous Leg Ulcers
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 128
- 试验地点
- 27
- 主要终点
- Time to 100% epithelialization of study ulcer
研究概览
简要总结
The overall objective of this study is to evaluate the effectiveness of dehydrated human amnion/ chorion membrane (dHACM) in reducing time to complete wound closure in patients with venous leg ulcers (VLUs).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Index ulcer characteristics:
- •Full-thickness venous leg ulcer for ≥ 30 days
- •Ulcer area after debridement is ≥ 1 cm² and ≤ 25 cm² at the randomization visit
- •Has a clean, granulating base with minimal adherent slough
- •Subject has completed 14 day run-in period with ≤ 25% wound area reduction post-debridement.
- •Have one of the following:
- •Ankle Brachial Pressure Index (ABI) > 0.
- •(Calculations will be made using measurements from both posterior tibial and dorsalis pedis arteries as well as both arms) OR
- •Have venous insufficiency confirmed by duplex ultrasound examination for valvular or venous incompetence.
- •Females of childbearing potential must be willing to use acceptable methods of contraception (birth control pills, barriers, or abstinence).
- •Ability to read/understand and sign Informed Consent and Release of Medical Information Forms.
- •Ability to understand and comply with weekly visits and follow-up regimen.
排除标准
- •Index Ulcer Assessment - Index ulcer meeting the following criteria will not be eligible for enrollment:
- •Penetrates down to muscle, tendon, or bone
- •Presence of another venous ulcer ≤ 2 cm from index ulcer
- •Is deemed by the Investigator to be caused by a medical condition other than venous insufficiency
- •Exhibits clinical signs and symptoms of infection
- •If in the opinion of the Investigator, the wound is suspicious for cancer, the subject should undergo an ulcer biopsy to rule out carcinoma. If carcinoma is ruled out, the subject may be re-screened.
- •Located on the dorsum of the foot or with more than 50% of the ulcer below the malleolus
- •Prior therapies - Subjects receiving treatment with any of the following will not be eligible for enrollment:
- •In the last 7 days - Negative pressure wound therapy of the index ulcer
- •In the last 7 days - Hyperbaric oxygen therapy
- •In the last 30 days - Treatment with cytotoxic chemotherapy, application of topical steroids to the ulcer surface, or use of ≥ 14 days of immune-suppressants (including systemic corticosteroids); or, subject is anticipated to require such medications during the course of the study
- •In the last 30 days - study ulcer treatment with any advanced therapy, including EpiFix®, tissue engineered materials (e.g. Apligraf® or Dermagraft®), or other scaffold materials (e.g. OASIS® Wound Matrix, MatriStem® Wound Matrix)
- •In the last 30 days - Subject has been on any investigational drug(s) or therapeutic device(s)
- •In the last 8 weeks - Amputation or revascularization (surgical or stenting) to the affected leg
- •Any history of radiation at the ulcer site
- •Any prior participation in a MiMedx® study
- •Study ulcer has undergone ≥ 12 months of continuous high strength compression therapy over its duration
- •Subject criteria that will make subject ineligible for enrollment:
- •Known osteomyelitis or active cellulitis at wound site
- •Hemoglobin A1C >12 in the last 60 days prior to randomization
- •Active malignant disease or subject is less than 1 year disease-free
- •NYHA Class III and IV congestive heart failure (CHF), as defined by the following criteria: Class III: Symptoms with moderate exertion; Class IV: Symptoms at rest
- •Auto-immune disorders including Systemic Lupus Erythematosus (SLE), Fibromyalgia, Acquired Immunodeficiency Syndrome (AIDS) or HIV
- •Allergy or known sensitivity to Aminoglycosides such as gentamicin sulfate and/or streptomycin sulfate
- •Known allergy to the components of the multi-layer compression bandaging, or who cannot tolerate MLCT
- •Presence of any condition (including current drug or alcohol abuse, medical or psychiatric condition) that is likely to impair understanding of or compliance with the study protocol in the judgment of the Investigator
- •Pregnancy at enrollment or within last 6 months, women who are breastfeeding, or women of childbearing potential who are planning to become pregnant during the time of the study OR are unwilling/unable to use acceptable methods of contraception (birth control pills, barriers, or abstinence)
研究组 & 干预措施
dHACM
Experimental
Application of multi-layer compression therapy with application of dHACM.
干预措施: Multi-layer compression therapy (Procedure)
dHACM
Experimental
Application of multi-layer compression therapy with application of dHACM.
干预措施: Application of dHACM (Other)
Control
Other
Application of multi-layer compression therapy without application of dHACM.
干预措施: Multi-layer compression therapy (Procedure)
结局指标
主要结局
Time to 100% epithelialization of study ulcer
时间窗: 12 weeks
次要结局
- Proportion of patients in both groups with complete wound healing at 12 weeks(12 weeks)
研究者
研究点 (27)
Loading locations...
相似试验
招募中
不适用
Dehydrated Human Amnion Membrane and Standard of Care Versus Standard of Care Alone in Nonhealing Diabetic Foot UlcersUlcer FootFoot UlcerDiabetic FootDiabetic Foot UlcerNCT06550596Axolotl Biologix100
已完成
不适用
Comparison of Dehydrated Human Amnion-Chorion and Type 1 Bovine Collagen Membranes for Guided Bone RegenerationRidge DeficiencyNCT03290638Samer Faraj43
进行中（未招募）
2 期
Human Amnion Membrane Allograft and Early Return of Erectile Function After Radical ProstatectomyProstate CancerErectile Dysfunction Following Radical ProstatectomyNCT05842057University of Miami118
已完成
不适用
Randomized Clinical Trial Using Amniotic Membrane in Robotic Assisted Laparoscopic ProstatectomyPudendal NerveNCT01832168MiMedx Group, Inc.34
Enrolling By Invitation
不适用
Effectiveness of AlloWrap® for the Reduction of Inflammation in ACDF ProceduresCervical StenosisCervical RadiculopathyCervical Disc DisorderSpondylolisthesisNCT04684901AlloSource50